13 results about "Respiratory epithelium" patented technology

A robust nasal organoid culture system and fully characterized 2D and 3D in vitro produced organoids are provided, as well as methods of using the organoids. The nasal organoids comprise a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for producing two-dimensional and three-dimensional nasal organoids are also provided. These methods generally require a two-phase culture system, i.e., amplification and differentiation culture. The provided nasal organoids are suitable for reproducing nasal tissue complexity, for mimicking respiratory diseases, studying barrier function and drug delivery, high throughput drug screening, and assessing the effects of pathogens and environmental toxins on nasal respiratory epithelium.

The present disclosure relates to a method for preparing a respiratory organoid by proliferating and differentiating respiratory epithelial cells. Unlike the conventional respiratory organoids in which epithelial cells existing in the apical region of the respiratory organ are generated on the interior of the organoid, the respiratory organoid of the present disclosure is shown in a form in which ciliated structures, which are epithelial cells, are located in the outer layer of the organoid, secretory cells are present on the interior, and basal stem cells existing at the base of respiratory tissue are also present on the interior of the organoid. It has a form similar to an actual respiratory tissue, and it was observed that the epithelial cells exhibited normal function, such as motility of ciliated cells. Therefore, when an organoid is prepared using the preparation method of the present disclosure, a respiratory organoid that can well mimic actual tissue can be prepared.

Provided herein are methods and compositions for identifying ionocytes from respiratory epithelial cells, and uses of such cells for treatment of inflammatory lung disease. Also provided herein are methods and compositions for modulating respiratory tract epithelial cell proliferation, differentiation, maintenance, and / or function.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The invention belongs to the technical field of biological medicines, and discloses a probiotic composition for preventing and treating respiratory tract infection as well as application and a product thereof. The probiotic composition provided by the invention contains the bifidobacterium longum subsp. Infantis i18 and the casei paracasei N1115. Compared with other combinations of bifidobacterium and casei paracasei, the specific combination of the bifidobacterium longum subsp. Infantis i18 and the casei paracasei N1115 not only has better adhesion to respiratory tract epithelial cells, but also can more remarkably reduce inflammatory response of inflammatory cells, effectively repair damaged respiratory tract epithelial cells and improve the respiratory tract epithelial cell repair effect. And the two compounds also show a more excellent synergistic effect in the aspect of inhibiting the growth of staphylococcus aureus. After breast milk oligosaccharide is added on the basis, the adhesive capacity to epithelial cells of the respiratory tract and the bacteriostatic activity to target pathogenic bacteria can be further enhanced. The invention can be applied to the fields of preparation of related food or medicines for prevention, treatment or adjuvant treatment of respiratory tract infection and the like.

To provide a method for preparing a respiratory organoid by proliferating and differentiating respiratory epithelial cells.SOLUTION: Unlike conventional respiratory organoids in which epithelial cells existing in an apical region of a respiratory organ are generated on an interior of the organoid, the respiratory organoid of the present disclosure is shown in a form in which ciliated structures, which are epithelial cells, are located in an outer layer of the organoid, secretory cells are present on the interior, and basal stem cells existing at a base of respiratory tissue are also present on the interior of the organoid. It has a form similar to an actual respiratory tissue, and it was observed to exhibit normal functions of the epithelial cells, such as motility of ciliated cells. Therefore, when an organoid is prepared using the preparation method of the present disclosure, a respiratory organoid that can well mimic the actual tissue can be prepared.SELECTED DRAWING: Figure 1

The present disclosure provides a use of a bacterial cellulose in treating and preventing airway diseases, especially the use in the treatment and prevention of inflammatory airway diseases associated with an impairment in airway epithelial cells such as asthma.

The application belongs to the technical field of biological medicine, and discloses application of xanthine in repairing respiratory epithelial injury drugs and a chronic obstructive pulmonary disease (COPD) organoid model construction and evaluation method. In view of the defects that existing treatment focuses on inflammation control, relies on multi-drug combination, lacks epithelial repair targeting and has low pathological similarity in vitro model, an airway-alveolus organoid model is innovatively constructed, the pathological chain of COPD airway injury-alveolus destruction can be completely reproduced, and a multi-dimensional evaluation system is established. Based on the model, it is first proved that xanthine single drug can significantly promote proliferation of damaged airway organoid cells, inhibit abnormal apoptosis, selectively down-regulate release of inflammatory factors such as TNF-alpha and CXCL1, promote alveolus organoid AT2 cell proliferation and regeneration, and repair alveolus homeostasis at a concentration of 20-100 muM without combination with other drugs. Xanthine is an endogenous purine metabolite, is safe and low-toxic, solves the pain points of existing drug combination dependence and side effects, and realizes upgrading from inflammation control to structure repair. Xanthine can be made into oral or respiratory tract local preparations, is suitable for repairing epithelial injury of respiratory diseases such as COPD and asthma, is suitable for a wide range of people, has significant clinical and industrialization values, and the innovative model also provides a reliable tool for related drug research and development.

Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.

The invention belongs to the field of agricultural microbe application, and particularly relates to an application of spirillum camarum CLA-AA-M04 in resisting pseudorabies virus infection. The trichospirillum is an anaerobic neutrophile bacterium and has a gram positive ultrastructure. The verification shows that the strain plays an antiviral role through the mechanisms of improving the respiratory tract barrier function, inhibiting virus replication, reducing inflammatory response and the like. By drenching the helispirillum caffei CLA-AA-M04, the virus load of the lung and brain of the PRV infected mouse can be obviously reduced, the survival rate is improved, the pathological injury of the lung is relieved, and the expression of inflammatory factors TNF-alpha and IL-6 is inhibited. In addition, the bacterial strain repairs the epithelial barrier function of the respiratory tract by up-regulating the expression of tight connection molecules, ZO-1 and Occludin and the expression of adhesion connection molecules E-cadherin and beta-catenin. The strain can be applied to preparation of a microbial preparation for resisting pseudorabies virus infection.

The invention provides a metabolism reprogramming culture medium, a metabolism reprogramming mesenchymal stem cell and a preparation method and application thereof, and relates to the technical field of stem cell culture, the metabolism reprogramming culture medium contains glucose and cell factors released by injured respiratory tract epithelial cells; the cell factors comprise at least one of IL-6 (interleukin-6), IL-8 (interleukin-8), IL-1beta (interleukin-1beta), TNF (tumor necrosis factor)-alpha, IFN (interferon)-gamma, MCP-1 (microcytidylcholine)-1, TGF (transforming growth factor)-beta, FGF2 ( And the content of glucose is 4000 to 5000 mg / L. In a high-glucose environment, damaged respiratory tract epithelial cells release cytokines to form a multi-factor regulation network, metabolism reprogramming of MSCs can be specifically induced, an efficient MSCs treatment product with definite functions is obtained, the problem that in the prior art, a culture medium is difficult to accurately simulate the influence of a disease complex microenvironment on the performance of MSCs is solved, and the MSCs treatment effect is improved. Therefore, the function enhancement effect of the preprocessed MSCs is limited and unstable.

Methods and compositions for modulating a target genome are disclosed. For instance, gene modifying systems may be used to insert a heterologous object sequence (e.g., encoding a chimeric antigen receptor) into a target cell. The target cell may be, e.g., a T cell, induced pluripotent stem cell, or respiratory epithelial cell.